PDF Cover

Mosunetuzumab Market

The market for Mosunetuzumab was estimated at $361 million in 2024; it is anticipated to increase to $550 million by 2030, with projections indicating growth to around $783 million by 2035.

Report ID:DS1802369
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Mosunetuzumab
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Mosunetuzumab Market Outlook

Revenue, 2024

$361M

Forecast, 2034

$729M

CAGR, 2025 - 2034

7.3%

The Mosunetuzumab industry revenue is expected to be around $387.0 million in 2025 and expected to showcase growth with 7.3% CAGR between 2025 and 2034. Building on this favorable outlook, the Mosunetuzumab market is gaining strategic importance as healthcare systems increasingly prioritize targeted immunotherapies for hematologic malignancies. Rising demand for personalized cancer treatment, expanding clinical adoption of innovative biologics, and growing investments in oncology research are reinforcing the therapy’s commercial relevance. Pharmaceutical companies are actively pursuing strategic collaborations, lifecycle management initiatives, and expanded clinical programs to strengthen market positioning. In parallel, supportive regulatory frameworks for breakthrough therapies, improved reimbursement pathways, and the expansion of specialized oncology centers are enhancing patient access. These factors collectively position Mosunetuzumab as a key growth contributor within the rapidly evolving immuno-oncology landscape.

Mosunetuzumab is a bispecific monoclonal antibody that simultaneously targets CD20-positive B cells and CD3-positive T cells, enabling the immune system to recognize and eliminate malignant B cells. It is primarily indicated for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, particularly follicular lymphoma, and represents an important advancement in off-the-shelf immunotherapy. Its targeted mechanism, fixed-duration treatment potential, and ability to activate T cells without individualized cell manufacturing differentiate it from several conventional therapies. Recent market trends include increasing evaluation in combination regimens, broader clinical research across additional B-cell malignancies, advancements in biomarker-driven treatment strategies, and growing investments in next-generation bispecific antibodies. Furthermore, AI-supported drug discovery, real-world evidence generation, and expanding precision oncology programs are accelerating innovation, while increasing physician confidence in immunotherapy continues to support demand for Mosunetuzumab across global oncology markets.

Mosunetuzumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Mosunetuzumab Market Outlook

Market Key Insights

  • The Mosunetuzumab market is projected to grow from $360.7 million in 2024 to $730 million in 2034. This represents a CAGR of 7.3%, reflecting rising demand across Oncology Hospitals, Cancer Research Institutes, and Specialty Clinics.

  • This is a highly consolidated market with 2 key players, where Genentech Inc. holds the dominant share.

  • U.S. and UK are the top markets within the Mosunetuzumab market and are expected to observe the growth CAGR of 4.7% to 7.0% between 2024 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.4% to 10.1%.

  • Slow adoption of How Is Bispecific Antibody Innovation Transforming the Mosunetuzumab Industry transition within key players in Mosunetuzumab market is creating a revenue window for adjacent and alternate markets like Rituximab and Brentuximab Vedotin to improve its use-case penetration in Oncology Hospitals and Cancer Research Institutes applications and expected to capture $26 million revenue from existing Mosunetuzumab market.

  • The Mosunetuzumab market is set to add $369 million between 2024 and 2034, with manufacturer targeting Cancer Research Institutes & Specialty Clinics Application projected to gain a larger market share.

  • With

    increasing prevalence of non-hodgkin lymphoma, and

    Provocative research and clinical trials, Mosunetuzumab market to expand 102% between 2024 and 2034.

mosunetuzumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Mosunetuzumab - Country Share Analysis

Opportunities in the Mosunetuzumab

The growing adoption of combination immunotherapy is also opening new growth avenues for Mosunetuzumab across hematologic oncology. Researchers are investigating its integration with checkpoint inhibitors, antibody-drug conjugates, and other targeted biologics to enhance therapeutic effectiveness in B-cell malignancies. Pharmaceutical partnerships and multicenter clinical trials are supporting broader label expansion and commercial development. The combination therapy segment for relapsed and refractory B-cell lymphomas is projected to experience the fastest growth, driven by rising investments in precision medicine across North America, Europe, and selected Asia-Pacific markets.

Growth Opportunities in North America and Europe

North America holds the largest share of the Mosunetuzumab market, driven by advanced oncology infrastructure, widespread adoption of precision medicine, and substantial investments in immuno-oncology research. The region benefits from strong clinical trial activity, favorable reimbursement frameworks, and the presence of leading biotechnology and pharmaceutical companies developing next-generation biologics. The most significant opportunity lies in expanding the use of bispecific antibodies across additional B-cell malignancies and combination immunotherapy regimens. Competition is intense, with established oncology drug manufacturers and emerging biotech firms actively advancing innovative targeted therapies and immunotherapies. Key market drivers include rising incidence of hematologic cancers, increasing physician preference for targeted treatment options, expanding regulatory support for breakthrough biologics, and growing healthcare expenditure. Strategic collaborations among pharmaceutical companies, academic institutions, and specialized cancer centers continue to accelerate commercialization, reinforcing North America's leadership in the global Mosunetuzumab market.
Europe represents a strategically important market for Mosunetuzumab, supported by strong public healthcare systems, expanding precision oncology initiatives, and increasing investment in advanced biologic therapies. Countries such as Germany, France, Italy, and the United Kingdom are strengthening access to innovative cancer treatments through favorable reimbursement policies and collaborative oncology research programs. The leading opportunity exists in relapsed or refractory B-cell lymphoma treatment, where demand for targeted immunotherapies continues to increase. Competition is characterized by multinational biopharmaceutical companies, regional biotechnology firms, and research organizations focused on bispecific antibody development and next-generation immunotherapies. Major market drivers include rising cancer prevalence, growing adoption of personalized medicine, expanding clinical research networks, and supportive regulatory pathways for innovative oncology products. In addition, strategic partnerships between healthcare providers and pharmaceutical companies are improving patient access and accelerating market penetration, positioning Europe as a key growth region for Mosunetuzumab commercialization.

Market Dynamics and Supply Chain

01

Driver: Expanding Bispecific Antibody Adoption and Rising Demand for Targeted Immuno-Oncology Therapies

The expanding adoption of bispecific antibody therapies is also a core growth factor driving demand for mosunetuzumab. Bispecific antibodies engage two targets simultaneously, enhancing immune cell recruitment against cancer cells. This targeted mechanism has also resonated with oncology specialists seeking more precise treatments that improve response rates while managing safety profiles. Alongside this, there is also a rising demand within immuno-oncology for therapies that can also address relapsed or refractory lymphomas where traditional monoclonal antibodies and chemotherapies fall short. Clinicians increasingly favor agents that harness the patient’s own T cells to eliminate tumor cells, positioning mosunetuzumab’s CD20 x CD3 bispecific design as a preferred choice. Together, these industry trends fuel portfolio diversification at cancer centers and support broader inclusion of bispecifics in treatment guidelines, ultimately enhancing clinical adoption and revenue generation in niche hematologic oncology markets.
A key market driver for mosunetuzumab is also the increased industry focus on outpatient cancer care and treatment convenience. Healthcare providers and patients alike are also seeking effective therapies that can also be administered safely in outpatient or specialty clinic settings, reducing the need for prolonged hospital stays. Mosunetuzumab’s manageable infusion profile and supportive safety monitoring make it suitable for delivery outside of intensive inpatient units. This trend aligns with broader shifts toward ambulatory oncology services, where convenience, reduced healthcare costs, and improved quality of life are also prioritized. As outpatient infusion capacity expands and clinician experience with bispecifics grows, mosunetuzumab benefits from heightened demand within community oncology practices and specialty clinics focused on delivering advanced biologic therapies efficiently and patient-centrically.
02

Restraint: Complex Safety Monitoring Requirements and Immune-Related Adverse Events Limit Wider Adoption

Mosunetuzumab’s T-cell engaging mechanism introduces safety challenges that act as a market restraint. Risks such as cytokine release syndrome and neurotoxicity require step-up dosing, close monitoring, and experienced clinical teams. This limits use to well-equipped oncology hospitals and delays adoption in smaller specialty clinics. For example, centers without intensive monitoring infrastructure may avoid prescribing it, reducing patient reach and slowing demand growth. These requirements also increase treatment costs and operational burden, which can affect reimbursement decisions. As a result, revenue generation remains concentrated in select institutions, constraining broader market penetration and influencing cautious prescribing behavior.
03

Opportunity: Can First-Line Follicular Lymphoma Treatment Expand Mosunetuzumab Market Potential and How Could Emerging Oncology Centers Improve Bispecific Antibody Accessibility

The increasing shift toward targeted first-line therapies is creating significant opportunities for Mosunetuzumab in follicular lymphoma management. Ongoing clinical studies are evaluating its use earlier in the treatment pathway to improve patient outcomes and reduce dependence on conventional chemotherapy. Strategic collaborations between biopharmaceutical companies and oncology research centers are accelerating clinical development and regulatory expansion. The first-line follicular lymphoma application is expected to witness the strongest growth, particularly in North America and Europe, where precision oncology adoption and access to advanced biologic therapies continue to increase.
The expansion of specialized oncology centers in emerging healthcare markets presents an untapped opportunity for Mosunetuzumab. Governments and healthcare providers are investing in advanced cancer treatment infrastructure, enabling greater access to innovative bispecific antibody therapies for patients with hematologic malignancies. Strategic licensing agreements, physician education initiatives, and improved reimbursement frameworks are supporting market penetration. The bispecific antibody application for relapsed or refractory B-cell lymphoma is anticipated to grow most rapidly across Asia-Pacific, where expanding oncology services and increasing healthcare investments are strengthening demand for advanced immunotherapies.
04

Challenge: Strong Competition from CAR-T Therapies and Emerging Bispecific Antibodies Pressure Demand

Intense competition from CAR-T cell therapies and next-generation bispecific antibodies is another major restraint for mosunetuzumab. CAR-T treatments, despite higher costs, offer durable responses that attract eligible patients and clinicians. At the same time, newer bispecific antibodies with differentiated dosing schedules or safety profiles are entering clinical practice. For instance, physicians may prefer alternative CD20 x CD3 agents perceived to have simpler administration or stronger efficacy data. This competitive landscape fragments demand, limits pricing flexibility, and challenges long-term revenue growth. Consequently, mosunetuzumab must compete aggressively for guideline inclusion and physician preference within a crowded immuno-oncology market.

Supply Chain Landscape

1

Raw Materials Sourcing

Lonza GroupWuXi Biologics
2

API Production

Genentech Inc.Lonza Group
3

Formulation & Fill Finish

Thermo Fisher ScientificCatalent Inc.
4

End Users & Applications

Oncology HospitalsCancer Research Institutes
Mosunetuzumab - Supply Chain

Use Cases of Mosunetuzumab in Oncology Hospitals & Cancer Research Institutes

Oncology Hospitals : In oncology hospitals, mosunetuzumab is primarily used as a bispecific CD20 x CD3 antibody therapy administered through intravenous infusion for patients with relapsed or refractory B cell lymphomas. These hospitals are the main end users due to their advanced infusion infrastructure, multidisciplinary oncology teams, and capability to manage immune related adverse events. The key advantage of mosunetuzumab in this setting is its off the shelf availability compared to personalized cell therapies, enabling faster treatment initiation. Oncology hospitals benefit from its targeted immune activation, which allows effective tumor cell killing while maintaining controlled dosing and monitoring in inpatient or outpatient hospital environments.
Cancer Research Institutes : Cancer research institutes utilize mosunetuzumab mainly within clinical trials and translational research programs to explore its broader therapeutic potential. In this application, the drug is used in its investigational and clinical grade form to study efficacy across different B cell malignancies and treatment lines. Research institutes focus on optimizing dosing schedules, combination strategies, and biomarker driven patient selection. A unique advantage in this segment is the ability of mosunetuzumab to provide insights into T cell engaging therapies without the complexity of cell manufacturing. This supports innovation in immuno oncology research and accelerates development of next generation bispecific antibody platforms.
Specialty Clinics : In specialty clinics, particularly hematology and oncology focused centers, mosunetuzumab is increasingly adopted for outpatient management of eligible lymphoma patients. The therapy is commonly administered as scheduled intravenous infusions under specialist supervision. These clinics value mosunetuzumab for its manageable safety profile and reduced logistical burden compared to intensive hospital based treatments. Its targeted mechanism enables effective disease control while supporting continuity of care closer to the patient’s home. Specialty clinics benefit from improved patient convenience, reduced hospitalization needs, and the ability to integrate advanced biologic therapies into routine practice for relapsed or refractory cancer populations.

Impact of Industry Transitions on the Mosunetuzumab Market

As a core segment of the Pharmaceutical industry, the Mosunetuzumab market develops in line with broader industry shifts. Over recent years, transitions such as How Is Bispecific Antibody Innovation Transforming the Mosunetuzumab Industry and Can Precision Oncology Ecosystems Accelerate Mosunetuzumab Market Expansion have redefined priorities across the Pharmaceutical sector, influencing how the Mosunetuzumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

How Is Bispecific Antibody Innovation Transforming the Mosunetuzumab Industry

The Mosunetuzumab industry is transitioning from conventional monoclonal antibody therapies toward next-generation bispecific antibody platforms that deliver more targeted and efficient cancer treatment. Pharmaceutical companies are increasing investments in innovative biologics, strategic licensing agreements, and clinical collaborations to expand therapeutic applications across hematologic malignancies. This transition is influencing associated industries such as biologics manufacturing, contract development and manufacturing organizations, and precision diagnostics. As demand for advanced immunotherapies grows, these sectors are expanding production capabilities, accelerating clinical development, and strengthening the commercialization ecosystem for targeted oncology therapies.
02

Can Precision Oncology Ecosystems Accelerate Mosunetuzumab Market Expansion

The rapid evolution of precision oncology is reshaping the Mosunetuzumab market by integrating biomarker-guided treatment strategies, companion diagnostics, and personalized care pathways. Healthcare providers, biotechnology companies, and diagnostic developers are collaborating to improve patient selection and optimize treatment outcomes through data-driven oncology approaches. This transition is generating broader opportunities across molecular diagnostics, digital health platforms, and specialized cancer care services. The growing emphasis on personalized medicine is encouraging healthcare systems to invest in advanced oncology infrastructure, creating a more connected ecosystem that supports wider adoption of bispecific antibody therapies and improves long-term commercial prospects.